Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02753816 · ClinicalTrials.gov registry record · NA
TXA Study in Major Burn Surgery
A NA study, sponsored by Corewell Health West.
- Terminated
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT02753816: Clinical Trial NA study, sponsored by Corewell Health West.
NCT02753816 is a NA study that was terminated before completion, run by Corewell Health West. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02753816, a NA study, was terminated before completion, sponsored by Corewell Health West.
- TERMINATED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
Major surgery can result in blood loss that can require a blood transfusion during and/or after surgery. Tranexamic acid (TXA) is a medication that was first introduced in the 1960's as a treatment for heavy menstrual bleeding. Over the past 20 years, it has been used and studied in patients undergoing open-heart surgery, liver transplantation, and urologic surgery. Investigators believe tranexamic acid may possibly decrease bleeding related to major burn surgery, resulting in reduced blood loss, lower blood transfusion rates, and possibly decreased hospital costs related to your stay. In this study, prior to each surgical procedure to treat the participants burn injury, the participant will receive either the drug tranexamic acid or placebo. The placebo is a liquid that looks like the tranexamic acid medicine, but does not have any active ingredient in it. In this study, both the tranexamic acid and the placebo are considered research.
Primary Outcome
To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries.
Interventions
- DRUG Tranexamic Acid
- DRUG Placebo Comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-04 |
| Est. Completion | 2019-12-03 |
| Phase | NA |
Why NCT02753816 stopped before completion
NCT02753816 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Tranexamic Acid is the first listed.
NCT02753816 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02753816 about?
NCT02753816 is a clinical study titled "TXA Study in Major Burn Surgery". Major surgery can result in blood loss that can require a blood transfusion during and/or after surgery. Tranexamic acid (TXA) is a medication that was first introduced in the 1960's as a treatment for heavy menstrual bleeding. Over the past 20 years, it has been used and studied in patients undergo...
What is the current status of trial NCT02753816?
This trial is currently terminated. It is a NA study. The enrollment target is 25 participants. The study started on 2016-04. Estimated completion is 2019-12-03.
What interventions are being tested in trial NCT02753816?
The interventions under investigation include: Tranexamic Acid (DRUG), Placebo Comparator (DRUG).
Who is sponsoring clinical trial NCT02753816?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02753816's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia